Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist
Objective: This study evaluated the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of eneboparatide (AZP-3601), a novel agonist of the PTH receptor 1 developed for the treatment of hypoparathyroidism. Design: This was a randomized, double-blind, placebo-controlled study. One-h...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2025-06-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | https://ec.bioscientifica.com/view/journals/ec/14/6/EC-24-0464.xml |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|